Two Sigma Advisers
AGIO icon

Two Sigma Advisers’s Agios Pharmaceuticals AGIO Stock Holding History

Two Sigma Advisers’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-85,200
Closed -$2.32M – 58
2025
Q4 		$2.32M Buy
85,200
+71,600
+526% +$2.51M ﹤0.01% 1122
2025
Q3 		$546K Buy
+13,600
New +$512K ﹤0.01% 1730
2025
Q1 		– Sell
-22,200
Closed -$729K – 2368
2024
Q4 		$729K Buy
+22,200
New +$1.04M ﹤0.01% 1613
2024
Q2 		– Sell
-20,900
Closed -$611K – 2422
2024
Q1 		$611K Buy
+20,900
New +$560K ﹤0.01% 1786
2022
Q1 		– Sell
-6,400
Closed -$210K – 2719
2021
Q4 		$210K Buy
+6,400
New +$258K ﹤0.01% 2275
2021
Q2 		– Sell
-16,500
Closed -$852K – 2430
2021
Q1 		$852K Buy
+16,500
New +$817K ﹤0.01% 1737
2020
Q4 		– Sell
-38,200
Closed -$1.34M – 2366
2020
Q3 		$1.34M Buy
+38,200
New +$1.67M ﹤0.01% 1369
2020
Q1 		– Sell
-35,100
Closed -$1.68M – 2445
2019
Q4 		$1.68M Buy
+35,100
New +$1.33M ﹤0.01% 1313
2019
Q3 		– Sell
-5,400
Closed -$269K – 2207
2019
Q2 		$269K Buy
+5,400
New +$289K ﹤0.01% 2048
2019
Q1 		– Sell
-34,200
Closed -$1.58M – 2284
2018
Q4 		$1.58M Buy
34,200
+7,300
+27% +$451K ﹤0.01% 1292
2018
Q3 		$2.08M Sell
26,900
-43,500
-62% -$3.5M 0.01% 1214
2018
Q2 		$5.93M Sell
70,400
-21,900
-24% -$1.91M 0.02% 783
2018
Q1 		$7.55M Sell
92,300
-14,500
-14% -$1.12M 0.02% 693
2017
Q4 		$6.11M Buy
106,800
+64,200
+151% +$4.04M 0.02% 782
2017
Q3 		$2.84M Buy
42,600
+200
+0.5% +$12K 0.01% 1042
2017
Q2 		$2.18M Buy
42,400
+5,200
+14% +$266K 0.01% 1158
2017
Q1 		$2.17M Buy
37,200
+4,900
+15% +$235K 0.01% 1214
2016
Q4 		$1.35M Buy
32,300
+18,300
+131% +$960K 0.01% 1392
2016
Q3 		$739K Buy
+14,000
New +$610K ﹤0.01% 1493

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Two Sigma Advisers's AGIO Position: Q1 2026 in Review

Two Sigma Advisers sold out of Agios Pharmaceuticals (AGIO) in Q1 2026, closing a stake of 85,200 shares — an estimated $2.32M sold.

Two Sigma Advisers first reported a position in AGIO in Q3 2016 and held it in 19 quarters. The position peaked at $7.55M in Q1 2018. 234 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Two Sigma Advisers reported no remaining Agios Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 85,200 Agios Pharmaceuticals shares in Q1 2026, an estimated $2.32M.
  • Two Sigma Advisers first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 19 quarters.
  • Two Sigma Advisers's Agios Pharmaceuticals position peaked at $7.55M in Q1 2018.
  • 234 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.